Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Zielinski, Christoph, Prof, Láng, István, Prof, Inbar, Moshe, Prof, Kahán, Zsuzsanna, Prof, Greil, Richard, Prof, Beslija, Semir, Prof, Stemmer, Salomon M, MD, Zvirbule, Zanete, MD, Steger, Günther G, MD, Melichar, Bohuslav, Prof, Pienkowski, Tadeusz, MD, Sirbu, Daniela, MD, Petruzelka, Luboš, Prof, Eniu, Alexandru, MD, Nisenbaum, Bella, MD, Dank, Magdalena, Prof, Anghel, Rodica, Prof, Messinger, Diethelm, MSc, Brodowicz, Thomas, MD
Published in The lancet oncology (01.09.2016)
Published in The lancet oncology (01.09.2016)
Get full text
Journal Article
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
Lang, Istvan, Prof, Brodowicz, Thomas, MD, Ryvo, Larisa, MD, Kahan, Zsuzsanna, Prof, Greil, Richard, Prof, Beslija, Semir, MD, Stemmer, Salomon M, MD, Kaufman, Bella, MD, Zvirbule, Zanete, MD, Steger, Günther G, MD, Melichar, Bohuslav, Prof, Pienkowski, Tadeusz, MD, Sirbu, Daniela, MD, Messinger, Diethelm, MSc, Zielinski, Christoph, Prof
Published in The lancet oncology (01.02.2013)
Published in The lancet oncology (01.02.2013)
Get full text
Journal Article